Xceleron
是一家从大学衍生出来的公司，这家公司在约克的中心科学实验室有一个重型的回旋加速器质谱仪，在药物开发的纳米技术应用方面处于领先地位。Xceleron公司将利用超灵敏加速质谱技术（AMS）开展研究工作。这个最灵敏的测试装置可以在临床研究的早期阶段得到药物代谢表达谱。这个分析工具可以使药物研发人员检测和测量出超低水平的已知和未知代谢产物的数据，这是用其他分析技术所不能得到的。

A journey toward Pharmaceutical Innovation
Founded in 1997 in York, UK, Xceleron provides bioanalytical Accelerator Mass Spectrometry (AMS) services for accelerated early drug development. The company uses ultra-sensitive AMS to investigate the pharmacokinetics and metabolism of developmental drugs in Phase 0, Phase I and Phase II/III clinical trials.

Xceleron pioneered human microtracer techniques as a way to accelerate drug development and has unmatched robust processes and knowledge of experimental design. There are currently 6 drugs on the market that have used Xceleron AMS data in filing, and another 3 in late stages of development. In 2008, the company opened its US facility in Maryland.

Xceleron's experience is especially valuable today because the characteristics of many contemporary small molecules (low solubility, long half-life and disproportionate human metabolites) mean that their early pharmacokinetic and metabolic characterization is critical to the cost-effectiveness of clinical development.

Our services can be tailored specifically for each project. We ensure that all aspects of an early human trial are managed quickly and cost-effectively.

Xceleron has been providing insight into early human drug development for more than 10 years and has conducted more GLP and GCP studies than any other CRO of its type.